Summary by Moomoo AI
eFFECTOR Therapeutics, Inc., a biopharmaceutical company based in Delaware, has filed a post-effective amendment with the Securities and Exchange Commission (SEC) on July 30, 2024, to deregister all unsold securities previously registered under two Registration Statements. The affected Registration Statements are No. 333-259751, initially filed on September 23, 2021, and subsequently amended, and No. 333-262339, filed on January 25, 2022. This move is in accordance with the company's undertakings to remove from registration any securities that remain unsold at the termination of the offering. The deregistration indicates that eFFECTOR Therapeutics will not be proceeding with the sale of these securities to the public. The company's Chief Executive Officer, Craig Jalbert, signed the amendment, indicating that eFFECTOR Therapeutics believes it meets all requirements for filing on Form S-1.
